The role of antimicrobial stewardship in curbing carbapenem resistance

Future Microbiol. 2013 Aug;8(8):979-91. doi: 10.2217/fmb.13.73.

Abstract

Antimicrobial resistance is a continuing, growing, worldwide iatrogenic complication of modern medical care. Carbapenem resistance among certain pathogens poses a significant challenge. In order to reduce the spread of these nearly untreatable pathogens, preventative efforts should be directed at reducing patient-to-patient transmission and preventing the emergence of resistance among susceptible strains. One theoretical intervention to reduce the emergence of resistance is establishing and strictly adhering to an antimicrobial stewardship program. However, data pertaining to the direct effect of stewardship in curtailing carbapenem resistance among epidemiologically significant organisms are scarce. In this report, we review the potential biases associated with data interpretation in this research field, and we review the data pertaining to the impact of stewardship in curbing carbapenem resistance in three significant groups of pathogens: Pseudomonas aeruginosa, Enterobacteriaceae and Acinetobacter baumannii.

Publication types

  • Review

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter Infections / prevention & control
  • Acinetobacter Infections / transmission
  • Acinetobacter baumannii / drug effects
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use*
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Cross Infection / transmission
  • Disease Transmission, Infectious / prevention & control
  • Drug Prescriptions / standards*
  • Drug Utilization / standards
  • Enterobacteriaceae / drug effects
  • Enterobacteriaceae Infections / drug therapy*
  • Enterobacteriaceae Infections / microbiology
  • Enterobacteriaceae Infections / prevention & control
  • Enterobacteriaceae Infections / transmission
  • Health Policy
  • Humans
  • Infection Control / methods
  • Organizational Policy
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / prevention & control
  • Pseudomonas Infections / transmission
  • Pseudomonas aeruginosa / drug effects
  • beta-Lactam Resistance*

Substances

  • Carbapenems